Search

Displaying results 3851 - 3860 of 5925 in total
  1. Drug

    Fenaperone

    go.drugbank.com/drugs/DB21281
    Experimental

    Fenaperone has a monoisotopic molecular weight of 376.22 Da.

  2. Drug

    Metrenperone

    go.drugbank.com/drugs/DB21312
    Experimental

    Metrenperone has a monoisotopic molecular weight of 407.2 Da.

  3. Drug

    Acefylline clofibrol

    go.drugbank.com/drugs/DB21353
    Experimental

    Acefylline clofibrol has a monoisotopic molecular weight of 420.12 Da.

  4. Drug

    Nelutroctiv

    go.drugbank.com/drugs/DB21554
    Investigational

    Nelutroctiv has a monoisotopic molecular weight of 543.13 Da.

  5. Drug

    Sofnobrutinib

    go.drugbank.com/drugs/DB21626
    Experimental

    Sofnobrutinib has a monoisotopic molecular weight of 498.19 Da.

  6. Drug

    Lacutoclax

    go.drugbank.com/drugs/DB21657
    Investigational

    Lacutoclax has a monoisotopic molecular weight of 922.36 Da.

  7. Drug

    Vilzemetkib

    go.drugbank.com/drugs/DB21704
    Experimental

    Vilzemetkib has a monoisotopic molecular weight of 642.27 Da.

  8. Drug

    Bromopride

    go.drugbank.com/drugs/DB09018
    Investigational

    Bromopride is a dopamine antagonist used as an antiemetic. Its prokinetic properties are similar to those of metoclopramide. It is unavailable in America or the United Kingdom.

    Categories: Dopamine D2 Receptor Antagonists
  9. Drug

    Prasterone

    go.drugbank.com/drugs/DB01708
    ApprovedInvestigationalNutraceutical

    In November 2016, DHEA was approved (as Intrarosa) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause

    International brands: OVIGYN-DCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  10. Drug

    Mipomersen

    go.drugbank.com/drugs/DB05528
    Approved

    Due to this serious risk of liver toxicity, mipomersen sodium is only available to patients under the restricted program called Kynamro Risk Evaluation and Mitigation Strategy program.